Antonella M. Conte

Is
Pozzilli, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 267 publications

Profiling the long-term risk of severe adverse events in a cohort of multiple sclerosis patients treated with different treatment sequences: Results from the Italian Multiple Sclerosis and Related Disorders Registry (I-MS&RD) (ProSA study).

Profiling the long-term risk of severe adverse events in a cohort of multiple sclerosis patients treated with different treatment sequences: Results from the Italian Multiple Sclerosis and Related Disorders Registry (I-MS&RD) (ProSA study).

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: July 04, 2026

CSF Cytokine Network Organization Predicts Progression Independent of Relapse and MRI Activity in Multiple Sclerosis.

CSF Cytokine Network Organization Predicts Progression Independent of Relapse and MRI Activity in Multiple Sclerosis.

Journal: Annals of clinical and translational neurology

Published: May 21, 2026

HD-MUNet: integrating artificial intelligence and high-density electromyography for motor unit number estimation.

HD-MUNet: integrating artificial intelligence and high-density electromyography for motor unit number estimation.

Journal: IEEE transactions on bio-medical engineering

Published: May 20, 2026

CORTICAL SIGNATURES ACROSS FACILITATORY NEUROMODULATION PROTOCOLS OVER THE PRIMARY MOTOR CORTEX: A TMS-EEG STUDY.

CORTICAL SIGNATURES ACROSS FACILITATORY NEUROMODULATION PROTOCOLS OVER THE PRIMARY MOTOR CORTEX: A TMS-EEG STUDY.

Journal: NeuroImage

Published: April 26, 2026

Cladribine in multiple sclerosis with autoimmune comorbidities: Further clinical insights from patients with rheumatologic disease treated in combination with secukinumab.

Cladribine in multiple sclerosis with autoimmune comorbidities: Further clinical insights from patients with rheumatologic disease treated in combination with secukinumab.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: April 26, 2026

Rapidly progressive dementia with parkinsonism in the Italian CJD Registry: underlying pathology and clinical-biomarker clues for differential diagnosis.

Rapidly progressive dementia with parkinsonism in the Italian CJD Registry: underlying pathology and clinical-biomarker clues for differential diagnosis.

Journal: Parkinsonism & related disorders

Published: April 23, 2026

Subcutaneous natalizumab administration in relapsing-remitting multiple sclerosis: results of EASIER 2 study.

Subcutaneous natalizumab administration in relapsing-remitting multiple sclerosis: results of EASIER 2 study.

Journal: Journal of neurology

Published: March 19, 2026

Resting-State EEG Microstates as Dynamic Biomarkers of Network Dysfunction and Cognitive Impairment in Patients With Multiple Sclerosis.

Resting-State EEG Microstates as Dynamic Biomarkers of Network Dysfunction and Cognitive Impairment in Patients With Multiple Sclerosis.

Journal: Neurology

Published: March 19, 2026

Correction: Enhancing the endocannabinoid system to treat residual disease in relapse-free multiple sclerosis.

Correction: Enhancing the endocannabinoid system to treat residual disease in relapse-free multiple sclerosis.

Journal: Frontiers in neurology

Published: March 13, 2026

Contribution of thalamus-cortex network and cortical habituation mechanisms in multiple sclerosis.

Contribution of thalamus-cortex network and cortical habituation mechanisms in multiple sclerosis.

Journal: Multiple sclerosis and related disorders

Published: March 02, 2026

Correction to: Exploring perceived gender disparities in neurology career: insights from an Italian survey.

Correction to: Exploring perceived gender disparities in neurology career: insights from an Italian survey.

Journal: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology

Published: February 16, 2026

Ocrelizumab in early relapsing-remitting multiple sclerosis: first interim analysis of the MUSPO Italian prospective cohort.

Ocrelizumab in early relapsing-remitting multiple sclerosis: first interim analysis of the MUSPO Italian prospective cohort.

Journal: Journal of neurology

Published: February 12, 2026

Showing 1-12 of 267

Last Updated: 09/26/2026